Neuroendocrinology News

ATLANTA — More than 90% of adults with acromegaly remained responders to oral octreotide 3 years after initiating treatment, according to findings from the MPOWERED open-label extension study presented at ENDO 2022.

ATLANTA — In this video exclusive, Maria Fleseriu, MD, FACE, reviews the pituitary research presented at the annual meeting of the Endocrine Society in Atlanta.

Among adults with controlled acromegaly, postmenopausal women had higher growth hormone levels than men despite similar insulin-like growth factor I levels, according to study data.

SAN DIEGO — Women with Sheehan’s syndrome and growth hormone deficiency have higher total cholesterol and triglycerides and higher inflammatory markers compared with healthy adults, according to a speaker.

SAN DIEGO — Osilodrostat is associated with improvements in physical manifestations of hypercortisolism and reductions in mean body weight and BMI in adults with Cushing’s syndrome, according to a speaker.

SAN DIEGO — Compared with placebo, levoketoconazole improved cortisol control and serum cholesterol levels for adults with endogenous Cushing’s syndrome, according to results from the LOGICS study presented here.

Adults with acromegaly are more likely to experience a vertebral fracture than those without the disease, and high growth hormone levels increase fracture risk, according to study data from Italy.

The use of an immunohistochemistry‒guided targeted amplicon sequencing approach using formalin-fixed, paraffin-embedded tissue detected somatic mutations in more than 70% of cortisol-producing adenomas, according to study data.

Among healthy adults, one night of moderate light exposure during sleep compared with sleep in a dimly lit environment increased nighttime heart rate and next-morning insulin resistance, concluded new research.

More than three-quarters of adults with Cushing’s disease assigned osilodrostat had a normalized mean urinary free cortisol level at 12 weeks and maintained a normal level at 36 weeks, according to data from the LINC 4 phase 3 trial.